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Abstract 
Clinical Genetic Services and Genomic research are rapidly developing but, historically, those with 
the greatest need are the least to benefit from these advances. This encompasses low-income 
communities, including those from ethnic minority and indigenous backgrounds. The “Genomix” 
workshop at the European Society of Human Genetics (ESHG) 2016 conference offered the 
opportunity to consider possible solutions for these disparities from the experiences of researchers 
and genetic healthcare practitioners working with underserved communities in the USA, UK and 
Australia. Evident from the workshop and corresponding literature is that a multifaceted approach 
to engaging communities is essential. This needs to be complemented by redesigning healthcare 
systems that improves access and raises awareness of the needs of these communities. At a more 
strategic level, institutions involved in funding research, commissioning and redesigning genetic 
health services also need to be adequately represented by underserved populations with intrinsic 
mechanisms to disseminate good practice and monitor participation. Further, as genomic medicine 
is mainstreamed, educational programmes developed for clinicians should incorporate approaches 
to alleviate disparities in accessing genetic services and improving study participation. 
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Introduction 
As genomics research enters its second decade after the completion of the International Human 
Genome Project, the research conducted still is not fully reflective of the diversity found in global 
populations. Underserved populations include both populations in low and middle-income countries 
and low-income communities in high-income countries. Although some efforts have been made to 
address disparities, the former continues to receive little attention even though there are many 
compelling reasons to do so e.g. achieving a greater understanding of genomic variation and 
reducing existing health inequalities (Christianson et al., 2013; Nippert, 2013).  
The latter includes minority and indigenous populations who have historically had poor access to 
genetic services. This has been seen both in general genetic services (Roberts, Cullen and Bundey, 
1996; Khan et al., 2010) as well as in specialist cancer services (Allford et al., 2014). The poor access 
of African-American women to BRCA1 genetic testing is a particularly relevant exemplar (Armstrong 
et al., 2005; Levy et al., 2011). Further, the provision of genetic screening programmes may also be 
inadequately developed in these communities e.g. a lack of pre and post-test counselling in neonatal 
sickle cell screening (Hussein et al., 2015).  
This article will focus on underserved populations in high-income countries in the context of the 
USA, UK and Australia and explore why recognising these disparities matter, indicate some reasons 
for their existence and based on a workshop at the European Society of Human Genetics (ESHG) 
conference in 2016, consider possible solutions for addressing them.  
 
Why does this matter? 
Tackling inequalities in genomics research and access to genomic medicine are important to enhance 
the scientific rigour of research conducted in genomics, improve the utility and applicability of their 
findings to underserved communities and to understand the impact of access on health outcomes. 
Some diseases are more common in certain populations. This could be autosomal recessive diseases 
due to founder mutations, population carrier rate or consanguinity while other conditions may be 
more common but without a clear inheritance e.g. prostate cancer in men of African descent 
(Metcalfe et al., 2008; Williams and Powell, 2009; Chornokur et al., 2011; Farrell et al., 2013; Martin, 
Starks and Ambs, 2013; Powell and Bollig-Fischer, 2013). The disease burden among migrant 
populations too are constantly evolving and the impact of Westernisation and globalisation means 
that there are new healthcare challenges that could be addressed through studying genomic 
variation (Garduño-Diaz and Khokhar, 2012; Dubé et al., 2015; Barlas et al., 2016). 
However, there is a caveat: discussions with African American, Latino and White communities in the 
USA suggest that, although gene-environment interactions contribute to group differences in health 
outcomes, social conditions trigger group-level genetic differences and, in particular, contribute to 
poorer health outcomes among African Americans (Isler et al., 2013). A review by Via et al also 
suggested that researchers have to be mindful of the correlation between genetic ancestry and 
socioeconomic and environmental factors that could underlie differences seen in the disparities 
between different ethnic groups (Via, Ziv and Burchard, 2009). 
Nevertheless, a lack of access to clinical genetics by these communities or a lack of awareness of 
these issues among healthcare professionals may have an impact on genetic testing and research 
and is likely to skew our understanding of human disease and variation. This, in turn, could make 
interpretation of results more difficult (Carlson et al., 2013; Manrai et al., 2016; Petrovski and 
Goldstein, 2016) and lead to poorer health outcomes in these communities (Modell et al., 2000; 
Susswein et al., 2008). This is evident in pharmacogenomics research where efficacy and side effects 
of certain drugs may be affected by genomic variation and ethnicity (Kaneko et al., 1999; Desta et 
al., 2004; Cohen et al., 2006; Hung et al., 2006). Moreover, in cancer research, disparities in cancer 
morbidity and mortality that adversely impacts underserved groups may in part be ascribable to a 
failure to include diverse populations in biospecimen banks (Lawson et al., 2015).  
However, all future research with underserved, particularly minority and indigenous communities, 
will have to overcome mistrust from historical malpractices (Gamble, 1997; Corbie-Smith et al., 
1999; Fairchild and Bayer, 1999; Scharff et al., 2010; Boyer et al., 2011; Sheppard et al., 2013; 
George, Duran and Norris, 2014). This includes the Havasupai Diabetes Project where blood samples 
consented for an investigation into the high incidence of diabetes amongst the Havasupai tribe were 
used to investigate genetic causes of schizophrenia, inbreeding and population migration theories 
without the tribe’s consent (Mello and Wolf, 2010; Pacheco et al., 2013). This mistrust has 
propagated within these communities and is ever present today. A survey of African American 
premedical students suggested that these students have several concerns about genetic testing- 
including discrimination, privacy and eugenics. Surprisingly these concerns were increased, not 
lessened, by genetics education (Laskey et al., 2003). 
The next section highlights solutions from a ESHG workshop to improve access of underserved 
groups to genetic services and research opportunity, particularly focusing on minority and 
indigenous communities. 
 
Possible Solutions 
Community engagement 
Critical to improving underserved communities’ access to genomic services and participation in 
genomic research is early community engagement. This involves working with communities to 
identify their needs and concerns. Strategies to address these could involve town hall meetings that 
are popular among African American communities in the USA (Ansell et al., 2009; Fouad et al., 2010; 
Schoenfeld and Francis, 2016) or more defined focus groups (Streicher et al., 2011; Walker et al., 
2014). The work of the National Centre for Indigenous Genomics (NCIG) at the Australian National 
University (ANU) with Aboriginal communities is an excellent example of the latter where focus 
groups were used to recognise disparities, address past poor research practice and explore themes 
concerning culture, kinship and genes, and the language of inheritance (Callaway, 2016). 
Focus studies conducted among African American and Latina/Latinos in the USA also identified 
communication strategies as a key tool to reduce barriers. This includes reducing language barriers, 
increasing dispersion of information via a variety of channels and engaging representatives from the 
communities of interest (Schulz, Caldwell and Foster, 2003). As such, multifaceted channels of 
communication facilitated by community leaders, faith leaders and patient champions could also be 
used to engage with these underserved communities and build trust (Yancey, Ortega and 
Kumanyika, 2006). The most successful of these strategies seem to be directed by the communities 
themselves e.g. videos produced by the Aboriginal communities with the NCIG and written material 
produced for the British Pakistani community in East Lancashire, UK. These efforts can also be 
reinforced by the use of role models or celebrities that can have a major impact on healthcare 
behaviour (Evans et al., 2014). 
Another example of community engagement is the outreach work in Leicester, UK. For many years 
the Leicester Genetics Education Centre of Excellence in Teaching and Learning  (GENIE) has a 
developed a reputation in community education outreach, from teaching DNA fingerprinting and 
promoting mental health awareness in schools to explaining how the remains of Richard III were 
identified through mitochondrial inheritance techniques (King et al., 2014). This led to the inception 
of the ‘Supporting Families with Cancer’ project with Macmillan Cancer Support which resulted in 
additional outreach events, stakeholder projects, primary care triage projects and developing the 
world's first YouTube channel for clinical genetics (Lakhani et al., 2013; Jones et al., 2016). The clear 
message from these projects was that patients felt that supporting general practitioners in the 
community make effective referrals into specialist services was a key principle to accessing good 
care. 
 
Redesign health care systems 
Beyond community engagement, it is important to offer tangible improvements to health care 
systems. This includes strategies to communicate with patients from linguistically diverse 
backgrounds. This is demonstrated in Victoria, Australia where nearly a quarter of its population 
speak 260 languages other than English at home. Victoria’s population is diverse and rapidly 
changing with 46.8% born overseas or having at least one parent born overseas and where the 
overseas-born population continues to steadily rise (Australian Bureau of Statistics, 2011).  
The Melbourne Genomics Health Alliance was a whole system approach to genomics driven by ten 
leading healthcare and research organisations in Victoria who came together to advance their joint 
interest in bringing genomics into healthcare. In 2013, the 7 founding members funded a 
collaborative and shared Demonstration project where patients with five diverse genetic conditions 
received genomic sequencing in parallel with standard care (Gaff et al., 2017). The major aim of the 
project was to understand patient experiences of having genomic sequencing and their preferences 
for this type of testing in the future- using surveys as the mode of data collection. Patients were 
recruited based on their condition; therefore, challenges were not related to testing access but 
around gaining feedback from these participants on their motivations, concerns, preferences and 
understanding of genomic testing. 
It was evident from this project that the experiences and preferences of Culturally and Linguistically 
Diverse (CALD) individuals will be important in determining the systemic changes that are required 
to overcome the challenges of embedding genomics into routine clinical practice. Preliminary data 
from the project demonstrated that 11% identified as English as a Second Language (ESL) with at 
least 18 separate first languages being spoken with little overlap. Although translation of the surveys 
into other languages was not deemed to be suitable due to the diversity of languages spoken, other 
strategies were implemented over the course of the project to increase survey participation from 
CALD individuals. These included exploring whether the survey could be completed with a family 
member, a trusted healthcare professional who can translate or over the telephone with a 
telephone interpreter. Melbourne Genomics now offers genomic sequencing to patients with 11 
different conditions. Further consultations are being conducted with Indigenous and CALD groups to 
determine if there are cultural sensitivities that require consideration when developing structures 
and policies regarding the management of genomic data. The Demonstration project clearly 
highlights the benefits of a whole system approach to genomics and particularly improving access to 
translators and language/culturally sensitive materials (Hussain‐Gambles, 2003) in engaging 
traditionally underserved communities.  
Improving access using genetic outreach workers, simplifying referral processes and multi-agency 
partnerships will also complement such efforts (Khan, Kerr and Kingston, 2016). The work done in 
East Lancashire, UK is a good example of the latter where a systems approach to improving 
engagement with the British Pakistani community was undertaken by an innovative collaboration 
between primary care organisations (PCOs), commissioning groups, public health and the regional 
genetic services.  
Approximately 30% of the population in East Lancashire is Muslim and of South Asian heritage. It has 
one of the highest child mortality rates in the country (Public Health England, 2016) with 41% of the 
deaths in under 18-year-olds resulting from a chromosomal, congenital or genetic disorder. With up 
to 75% of British Pakistanis in the region being in a consanguineous marriage and with no indications 
of a decline in this practice, the need to engage with this community was identified.  
However, traditionally, uptake among these families have been poor as the utility of this service is 
not recognised (Khan et al., 2010). As such, a multi-stranded approach that included investments at 
the community level, alongside genetic service enhancement and training of healthcare 
professionals was employed that has proven to be more effective than single stranded approaches. 
A key to the success of this approach has been the provision of enhanced genetics advice which 
included no language barriers, an understanding of, and sensitivity towards, the cultural context in 
which decisions are being made including gender, religion and cultural complexities. Healthcare 
inequalities have been reduced in East Lancashire through this collaborative approach. Families are 
presenting for information/support who hadn’t previously attended clinics. 
 
Strategic level changes 
Ensuring that underserved populations are involved in genetic and genomic projects currently relies 
on pockets of good practice by interested parties. To ensure that this is consolidated, sustained and 
rolled out to other groups will require fundamental institutional level changes (Popejoy and 
Fullerton, 2016) such as the changes delivered by the Athena SWAN Charter for women in science. 
Under-representation of women in academia is an internationally recognised disparity that has 
persisted through time. This is particularly evident in academic medicine where just 28% of clinical 
academics in the UK are women. This disparity exacerbates with seniority as although women 
account for 42% of lecturers, only 18% are professors (Medical Schools Council, 2015). 
Amidst this background of gender-inequality, the Athena SWAN Charter gender equality award 
scheme is one initiative that has made some inroads to tackle the prevailing disparity. The Charter 
established in 2005 by the Equality Challenge Unit (ECU) was instituted to encourage and recognise 
efforts to advance the careers of women in science, technology, engineering, maths and medicine 
(STEMM) (Caffrey et al., 2016). Since 2011, biomedical research units, biomedical research centres 
and patient safety translational research centres that apply for National Institute for Health Research 
(NIHR) approved grants are required to reach a certain level of compliance with a series of outcome 
measures for improving the number of, and opportunities for, female academics in their respective 
institutions. The Athena SWAN has had a positive impact in advancing gender equality and although 
there is limited evidence at present to attribute the Athena SWAN to the observed increase in 
women in academic medicine (Gregory-Smith, 2015), it has raised awareness of gender inequality in 
the workplace and has brought about important structural and cultural changes to address gender 
inequality. A key to the success of this initiative may have been linking the Athena SWAN to 
government research funding (Ovseiko et al., 2017).  
As such, similar initiatives may also be used to facilitate adequate representation of underserved 
populations in genomic research and as patient representatives at all levels e.g. grant committees, 
ethics committees and research steering groups. Grant selection criteria, ethical approval and 
research progress reports should also include ongoing assessments of the representativeness of 
study populations. Moreover, patients from underserved communities and researchers with an 
interest in healthcare access equality need to actively participate in and apply lobbying pressures on 
commissioning groups to ensure that initiatives that address disparities are kept at the forefront of 
discussions on service design and research specification. 
Further, clinicians serving underserved populations will need ongoing education on advances in 
genomic medicine and management approaches based on genetically determined variants (Feero 
and Green, 2011; Radice et al., 2011). Although understanding which genomic variants are medically 
actionable beyond standard phenotypic information will require ongoing efforts to improve patient 
participation from diverse backgrounds, educational strategies to reduce inequalities in access as 
well as developing an understanding of cultural factors in minority communities should be pursued.  
Research databases should also be sufficiently powered with participants from ethnic minority 
groups and other underserved communities to draw meaningful conclusions (Chow-White and 
Duster, 2011; Lawson et al., 2015). This applies to studies such as the UK 100,000-genome project 
with its aims to develop a matched genomic variant and clinical phenotype anonymised data set in 
an agreed, standardised and unified format with longitudinal pulled through data sets to assist with 
national and international clinical research and commercially driven collaborations to improve our 
understanding of human variation and how this links to disease and influences healthcare outcomes 
given therapeutics interventions. This can also be enhanced through replication studies in other 
countries if these are widely accessible and in a readable and usable format. As society becomes 
increasingly diverse, this also includes embracing more objective measures of genetic makeup 
beyond traditional definitions of race and ethnicity (Mersha and Abebe, 2015).  
Finally, the coding of ethnic group status in referrals to genetics services and participation in 
genomic projects needs to be accurate so that healthcare outcomes and access to new technologies 
can be prospectively compared for the studied populations. This data is currently often incomplete 
and needs to be more routinely and systematically captured. Further, the success of strategies that 
address disparities also needs to be documented using practical metrics, for example, increase in 
appropriate referrals, increase uptake in the extended family and, in the case of reproductive 
genetic risk, reduced infant morbidity and mortality.  
 
Conclusion 
Inequality of access to new types of medical technologies through socioeconomic or ethnicity 
barriers are likely to accentuate healthcare disparities. There are moral, scientific and historic 
reasons why including underserved groups in Genomic Medicine projects and research is advisable 
to truly understand human genomic variation and improve healthcare outcomes. This will require 
multi-faceted culturally sensitive, educational and outreach based approaches that simplify patient 
pathways and are underpinned by understanding the needs of and working with, local communities. 
With the drive towards personalised medicine, it is imperative that existing inequalities in genomics 
research and disparities between communities are addressed to prevent exacerbating them. 
Targeted education and outreach could help to engage minority communities and break down the 
barriers that hinder access to genetic services. However, the current definitions of race and ethnicity 
limits the ability to assess recruitment to genomic research and the time has come for medical 
research to embrace more objective measures of genetic makeup. 
 
Recommendations 
Community Engagement 
I. Use multifaceted channels of communication with the aid of patient champions, faith 
leaders and community leaders to engage with and educate underserved populations 
II. Enable general practitioners in the community to make effective referrals to specialist 
services 
Redesign health care systems 
I. Improve access to translators and language/culturally sensitive material 
II. Use multi-stranded approaches in a multi-agency manner to engage with communities and 
advance joint interests 
Strategic level changes 
I. Implement institutional changes in grant requests and service design and ensure there is 
adequate representation of underserved communities at all levels 
II. Provide ongoing education for clinicians serving underserved populations in advances in 
genomic medicine and strategies to tackle disparities in access and research participation 
among underserved communities 
III. Ensure databases are adequately powered by individuals from underserved communities 
IV. Complete ethnic minority coding in referrals and utilise practical metrics to document 
success of strategies 
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